185 result(s)
Home Medical Affairs
Get access to the latest news and research in medical affairs with this comprehensive portal. Stay up-to-date with the latest clinical trials, studies, and developments in the medical field. Explore a variety of resources to enhance your knowledge and stay informed.
Contact Us Confirmation
Solicite la visita de uno de nuestros delegados de GSK- Confirmación
CAPTAIN Study Clinical Remission Poster: ATS 2024
Poster from ATS 2024 presenting the post hoc analysis of clinical remission from the CAPTAIN study.
CAPTAIN Study sub-group analysis video
The CAPTAIN study provides robust evidence to support, and better tailor, the use of triple therapy in asthma using a precision medicine approach. In this video, Professor Ian Pavord presents a sub-group analysis from the CAPTAIN study exploring the impact of type 2 biomarker status on outcomes.
Clinical Remission in Asthma
A collection of materials addressing Clinical Remission in asthma which is an ambitious but attainable treatment goal for patients with asthma irrespective of disease severity and treatment history
AAAAI 2024 CAPTAIN study post-hoc Clinical Remission oral presentation (key take aways video)
Video recording of Prof. Oppenheimer presenting key takeaways from the CAPTAIN clinical remission post hoc analysis results from AAAAI 2024
Audio for the FULFIL Study Post Hoc Analysis Poster P630 at ATS 2024
Audio of Prof. David Singh presenting the FULFIL Study Post Hoc Analysis at ATS 2024
What is Clinical Remission concept video
Video recording of Prof. Oppenheimer providing an overview of clinical remission in asthma
CAPTAIN Study main results video
The CAPTAIN study provides robust evidence to support, and better tailor, the use of triple therapy in asthma using a precision medicine approach. In this video, Professor Ian Pavord presents the main results from the CAPTAIN study
Audio for the FULFIL Study Post Hoc Analysis Poster P630 at ATS 2024
Audio of Prof. David Singh presenting the FULFIL Study Post Hoc Analysis at ATS 2024
GAA May Webinar_ Lavoie Pre-recorded video
GSK-GAA Webinar 2024: Optimising evidence through a patient-centred approach
GAA May Webinar_ Panel Pre-recorded video
GSK-GAA Webinar 2024: Panel Discussion
MoD video (localisable version)
Short video summarising the IL-5 biology and recent evidence surrounding this science, as well as the cells impacted directly and indirectly by the IL-5 pathway.
uUTI Mechanism of Disease Video
The CAPTAIN study provides robust evidence to support, and better tailor, the use of triple therapy in asthma using a precision medicine approach. In this video, Professor Ian Pavord presents the main results from the CAPTAIN study
GAA May Webinar_ Yorgancıoğlu Pre-recorded video
GSK-GAA Webinar 2024: Personalized Asthma Care in the Clinic - Applying the latest evidence
NMA in Triple Therapy summary
For FF/UMEC/VI, the NMA suggest favourable efficacy compared with other single-inhaler triple therapies.
CAPTAIN Study Clinical Remission Poster: ATS 2024
Poster from ATS 2024 presenting the post hoc analysis of clinical remission from the CAPTAIN study.
NMA in Triple Therapy: Class comparison data in COPD
FF/UMEC/VI versus triple and dual bronchodilator therapies
The EMAX trial
Asthma is a heterogeneous disease and its management is multifactorial; many patients often remained uncontrolled despite treatment. HCPs have a critial role in identifying and managing patients who are not adequately controlled, which involves: -Regular discussions with patients -Recognition of symptoms and exacerbation risks -Continuous assessment of treatment -Reassessment of treatment and follow-up
Inhaled molecules for COPD treatment
How does molecule pharmacology correlate with clinical efficacy and safety? Pharmacological properties of inhaled respiratory molecules are critical to ensure the best possible clinical outcomes.
Network Meta-analysis (NMA) introduction for Triple Therapy
Comparing efficacy of triple therapies among patients with COPD. Multiple RCTs have demonstrated the benefit of triple over dual inhaled therapy in improving lung function and reducing the risk of exacerbation for patients with COPD
Inhalers in Respiratory Medicine > Unmet Need
In this section the symptom burden and unmet needs of patients with COPD are discussed, as well as the importance of correct inhaler technique and the impact of multiple inhaler therapy.
Inhalers in Respiratory Medicine >Patient Benefits
What are the key considerations affecting inhaler choice, from a patient and physician perspective?
Inhalers in Respiratory Medicine >Clinical Efficacy
Clinical efficacy of inhaled therapy delivered via the Ellipta inhaler. As well as ease of use, and fewer patients making an error with their inhaler, treatments are needed that show clinical efficacy.
RWE interactive map 2024
An interactive map displaying RWE studies in asthma, CRSwNP, EGPA, COPD and HES
EAACI 2024: Medical booth IL-5 digital infographic
Interactive pdf explaining the impact of IL-5 beyond eosinophils on cells. including its role in a variety of pathophysiological processes
AAAAI 2024 CAPTAIN study post-hoc Clinical Remission oral presentation (full video)
Video recording of Prof. Oppenheimer presenting key takeaways from the CAPTAIN clinical remission post hoc analysis results from AAAAI 2024
Impact of varying health status thresholds on disease stability in COPD with FF/UMEC/VI: IMPACT post hoc analysis.
Halpin MGD, et al. By demonstrating the effect of inhaled therapies on measures of health status (SGRQ and CAT) according to different thresholds, it may be possible to better assess disease stability in clinical practice. Disease stability should be considered an ambitious, practical and realisable treatment goal for patients with COPD, with the potential to guide patient management. Poster PA1173
Impact of varying lung function thresholds on disease stability in COPD with FF/UMEC/VI: IMPACT post hoc analysis.
Halpin MGD, et al. By demonstrating the effect of inhaled therapies on different lung function thresholds, it may be possible to better assess disease stability in clinical practice. Disease stability should be considered an ambitious, practical and realisable treatment goal for patients with COPD, with the potential to guide patient management. Presentation OA4653
Towards disease stability in COPD management: patient perspectives
Brooke M, et al. Patient advocacy advisors highlight disease stability as a desirable treatment goal for COPD, driven by patient aspirations and clinical characteristics. Personalisation of treatment strategies and patient care underpins the achievement and maintenance of disease stability resulting in improvements to the quality of life for patients living with COPD. Poster PA1171
Characteristics of severe eosinophilic asthma
Severe asthma with eosinophilic phenotype is a distinct phenotype of severe asthma. This phenotype is characterized by airway inflammation, increased blood/sputum eosinophil (EOS) concentrations, poor asthma control, and increased rate of exacerbations.
Real-world assessment of clinical remission in asthma with biologics Howarth P, et al. Poster PA2182
ERS Poster
ERS 2024 SOOTHE Study Poster
Smith JA, et al. Prior and concomitant medication use in patients with refractory chronic cough: post-hoc analysis of SOOTHE. ERS 2024. Poster No. PA319
Expert video describing disease stability
Video by Prof Dave Singh and Prof MeiLan Han describing disease stability and what it might mean for patients.
RCC Mechanism of Disease Loop Video
Short video looking at the pathophysiology of refractory chronic cough
Medical COPD portfolio symposium summary video_ERS 2024
Short video with the faculty, summarising the key takeaways of the symposium.
Refractory Chronic Cough Patient Story video
Short Video of RCC patient sharing the burden of this disease
Talking Head Video
Short Talking Head Videos outlining the unmet need in Refractory Chronic Cough and the importance of early recognition
Han, M.K., Vanfleteren, L.E.G.W., Kolterer, S. et al. Striving for Stability in Patients with COPD: A New Way Forward?. Adv Ther (2024)
ERS 2024 supplemental symposium report
ERS 2024 Asthma Symposium - Summary
Can we break through the therapeutic ceiling in severe asthma? Prof. Celeste Porsbjerg - Professor of Severe Asthma - Bispebjerg Hospital, Denmark
ERS 2024 Asthma Symposium
Full symposium recording of Can we break through the therapeutic ceiling in severe asthma? Prof. Celeste Porsbjerg - Professor of Severe Asthma - Bispebjerg Hospital, Denmark
Impact of varying lung function threshold on clinical remission in asthma with FF/UMEC/VI: CAPTAIN post hoc analysis.
Poster PA1199 from ERS 2024 presenting post hoc analysis of clinical remission from the CAPTAIN study.
Assessment of the components of clinical remission with moderate–severe asthma after 24–52 weeks of treatment: CAPTAIN post hoc analysis
Poster PA1198 from ERS 2024 presenting post hoc analysis of clinical remission from the CAPTAIN study.
Characteristics of patients meeting the components of clinical remission: CAPTAIN post hoc analysis.
Poster PA1197 from ERS 2024 presenting post hoc analysis of clinical remission from the CAPTAIN study.
ERS 2024 - COPD Portfolio Symposium
Full recording of Striving for Disease Stability in COPD. Giving patients more if their best days. Co-Chairs by Meilan K. Han and Dave Singh Prof. MeiLan Han: Prof of Medicine, Divison of Pulmonary and Critical Care - University of Michigan, USA. Prof. Dave Singh: Prof of Respiratory Pharmacology, University of Manchester, UK. Dr. Lowie Vanfleteren: Head of the COPD Center - Sahgrenska University Hospital, Goffenburg, Sweden.
CAPTAIN Clinical Remission ERS Poster Mod-Sev Audio for poster PA 1197
Audio to support poster PA1197 from ERS 2024 presenting the post hoc analysis of clinical remission from the CAPTAIN study.
CAPTAIN Clinical Remission ERS lung function; audio for poster PA1199
Audio to support poster PA1197 from ERS 2024 presenting the post hoc analysis of clinical remission from the CAPTAIN study.
CAPTAIN Clinical Remission ERS baseline; audio for poster PA1198
Audio to support poster PA1197 from ERS 2024 presenting the post hoc analysis of clinical remission from the CAPTAIN study.
Efficacy and safety of twice per year depemokimab in chronic rhinosinusitis with nasal polyps (ANCHOR-1 and ANCHOR-2): phase 3, randomised, double-blind, parallel trials. Prof. Philippe Gevaert
Full results from our positive ANCHOR-1 and ANCHOR-2 phase III clinical trials, with late-breaking data published in The Lancet.
2025 AAAAI/WAO Joint Congress
Full results from our positive ANCHOR-1 and ANCHOR-2 phase III clinical trials, with late-breaking data published in The Lancet.
ATS 2025
Full results from our positive ANCHOR-1 and ANCHOR-2 phase III clinical trials, with late-breaking data published in The Lancet.
Benefit of Early Versus Delayed Intervention With Mepolizumab in Patients With Severe Uncontrolled Asthma (SUA): A Retrospective Cohort Study. Corbridge T, et al.
Early initiation of mepolizumab can reduce the burden of asthma exacerbations, OCS usen and hospitalisations in patients with SUA, and highlights the need for timely identification and treatment of these patients
Mepolizumab Is Efficacious in Patients With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) With One or Multiple Prior Nasal Polyps (NP) Surgeries: SYNAPSE Outcomes Han JK, et al.
Mepolizumab significantly improves outcomes in patients with CRSwNP with 1 or mutliple prior NP surgeries
The Impact of Paroxetine, a Strong CYP2D6 Inhibitor, on the Pharmacokinetics and Safety of Camlipixant in Healthy Participants Satia I, et al.
American Academy of Allergy, Asthma & Immunology Poster 714
Low Adherence to Current Biologic Therapies in Asthma: Insights From a Retrospective Cohort Analysis of Claims Data Kwiatek J,et al.
Adherence to biologics among US patients with asthma is lower than previously reported, highlighting the eed for improved adherence monitoring.
Long-term safety of mepolizumab for up to ∼10 years in patients with severe asthma: open-label extension study. Pavord I, et al.
This Long-Term Access Program assessed the safety and benefit:risk of mepolizumab in pediatric, adolescent, and adult patients with severe asthma. The safety analysis was consistent with previous reports, with ni emerging safety concerns.
ANCHOR-1 and ANCHOR-2 Studies of Depemokimab in Chronic Rhinosinusitis With nasal Polyps
Study Objective and Design of ANCHOR 1 and 2 studies.
SWIFT-1 and SWFT-2 Studies od Depemokimab in Svere Asthma
Overall Study objective and Design of SWIFT-1 and SWIFT-2 studies
Efficacy and Safety of Twice-Yearly Depemokimab in Patients With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP): The Phase III Randomized, Double-Blind, Placebo-Controlled Replicate ANCHOR-1/2 Trials. Han JK, et all
Full results from our positive ANCHOR-1 and ANCHOR-2 phase III clinical trials, with late-breaking data presented at the 2025 American Academy of Allergy, Asthma and Immunology (AAAAI) and World Allergy Organization (WAO) Joint Congress in San Diego and simultaneously published in The Lancet.
Twice-Yearly Depemokimab Demonstrates an Acceptable Safety Profile in a 12-Month Interim Analysis of the AGILE Phase III Open-Label Extension Study Jackson DJ, et al.
Long term depemokimab was well tolerated with safety and efficacy profiles consistent with those in SWIFT-1/2 studies and demonstrating sustained efficacy for patients remaining on depemokimab
Depemokimab Reduces Exacerbations in Patients With Type 2 Asthma Characterized by Blood Eosinophils Across a Range of Blood Eosinophil and IgE Levels: SWIFT Subgroup Analyses Bernstein D, et al.
Twice-yearly depemokimab demonstrates consistend exacerbation reduction in patients with asthma across a range of baseline type 2 biomarkers measurements
Mepolizumab Improves Patient Reported Outcomes and Reduces Treatment Burden in Patients With Chronic Rhinosinusitis With Nasal Polyps: A Real-World Chart Review Study. Edgecomb AG, et al
In real-world practice, mepoluzimab substantially improves SNOT-22 score treatment burden, and symptoms in patients with CRSwNP
Greater Odds of Clinical Remission With Mepolizumab Versus Placebo in Severe Asthma: A 24-Week Individual Patient Data Meta-Analysis of RCTs Gould S, et al.
Patients with severe asthma not receiving mOCS are more likely to achive clinical remission components when receiving mepolizumab compered with placebo
The Impact of Itraconazole, a Strong CYP3A4 Inhibitor, on the Pharmacokinetics and Safety of Camlipixant in Healthy Participants Peters A, et al.
American Academy of Allergy, Asthma & Immunology Poster 714
Mepolizumab Reduces Systemic Corticosteroid (SCS)-Related Toxicities Compared to Chronic SCS Use in Patients With EGPA. Pongdee T, et al
Patients with EGPA in a real)world setting, mepolizumab treatment significantly reduces the overall occurrende of acute and chronic SCS-related toxicities and reduces HRU compered with patients receiving chronic SCS treatment
Effect of mepolizumab in airway remodeling in patients with late-onset severe asthma with an eosinophilic phenotype
This study investigates the efficacy of mepolizumab in patients with late-onset severe eosinophilic asthma and fixed obstruction3. Results suggest that mepolizumab treatment leads to clinical improvement and reduces indices of airway tissue remodeling, indicating a potential disease-modifying effect.
Interleukin-5 as a pleiotropic cytokine orchestrating airway type 2 inflammation: Effects on and beyond eosinophils Buchheit KM, et al.
Interleukin-5 (IL-5) is a key driver of eosinophils, key effector cells in the pathophysiology in many upper and lower airway diseases. However, recent evidence suggests that eosinophil-depletion alone may not account for all of the therapeutic effects of anti-IL-5 therapy and that IL-5 may also contribute to disease independently of its effects on eosinophils.
Eosinophils and tissue remodeling: Relevance to airway disease
Eosinophils play a cardinal role in airway remodeling both in health and disease, driving epithelial homeostasis and extracellular matrix turnover, impacting patient outcomes in severe asthma and CRSwNP.
GSK Medical Affairs - Contact
Contacte con el centro de información, solicite la visita de un delegado o el contacto por el departamento médico, Notifique de una sospecha de reacción adversa
Jackson, D.J. et al. Twice-Yearly Depemokimab in Severe Asthma with an Eosinophilic Phenotype. NEJM (2024)
NEJM publication of the phase III SWIFT studies investigating the efficacy and safety of depemokimab in severe asthma.
Depemokimab efficacy/safety in patients with asthma on medium/high- dose ICS: the Phase IIIA randomised SWIFT-1/2 studies.
Presentation from ERS 2024 of the phase III SWIFT studies investigating the efficacy and safety of depemokimab in severe asthma.
Depemokimab PK/PD in the 52-week randomised double-blind multicentre Phase III SWIFT-1 trial.
Presentation OA3647 from ERS 2024 of the PK/PD assessment of depemokimab in the phase IIIA SWIFT-1 trial.
Enhanced in vitro potency of depemokimab for interleukin-5 inhibition versus mepolizumab.
Presentation OA3644 from ERS 2024 of an in vitro study assessing the relative potency of depemokimab and mepolizumab.
Patient video: "Living with unstable COPD: A patient's story"
This is a short video summarising the patient burden of living with COPD.
Patient video: "Looking forward: patient's hopes for COPD care"
a short video summarising the patient hopes for COPD care
Patient video: "Disease stability: a patient's perspective"
a short video summarising the patient perspective of disease stability
Uncovering the hidden truth behind chronic rhinosinusitis with nasal polyps
Type 2 inflammation in CRSwNP
Understanding severe asthma
Type 2 inflammation in Severe Asthma
Belantamab Mafodotin + Bortezomib + Dexamethasone versus 2L+ Relapsed/Refractory Multiple Myeloma Regimens: Lenalidomide-Exposed, Lenalidomide-Refractory, High-Risk Cytogenic, and 2L-Only Subpopulations: A Network Meta-analysis
This indirect comparison of RCT's indicates that belantamab mafodotin and dexamethasone offers the highest PFS,OS and ORRR of the included PI-based regiments for 2L+RRMM
Patient-Centered Care in Hematology: How Side Effect Severity Influences Decision-Making Autonomy in RRMM
(Reused with permission from the American Society of Hematology. © 2024 The Authors. All rights reserved. Officially licensed by ASH for distribution via GSK Medical Affairs Website and reactively by GSK)
Efficacy of Belantamab Mafodotin + Bortezomib + Dexamethasone versus 2L+ Relapsed/Refractory Multiple Myeloma Regimens: Lenalidomide-Exposed, Lenalidomide-Refractory, High-Risk Cytogenic, and 2L-Only Subpopulations: A Network Meta-analysis
This indirect comparison of RCT's indicates that belantamab mafodotin and dexamethasone offers the highest PFS,OS and ORRR of the included PI-based regiments for 2L+RRMM
Updated results from DREAMM-3, a phase 3 study of belantamab mafodotin (Belamaf) versus pomalidomide plus dexamethasone in patients (pts) with relapsed/refractory multiple myeloma (RRMM)
Longer-term follow-up of DREAMM-3 showed improved PFS and OS over time, suggesting a greater depth and durability of response for belantomab mafodotin vs pomalidomide plus dexamethasone
Characterization and management of ocular events in patients treated with belantamab mafodotin plus bortezomib and dexamethasone (BVd) in the DREAMM-7 study
Belamaf dose modifications managed ocular events through an individuak dosing schedule based on patients tolerability, therby allowing patients to remain in treatment and continue to derive benefit
Characterization and management of ocular events in patients treated with belantamab mafodotin plus pomalidomide and dexamethasone in the DREAMM-8 study
Belamaf dose modifications managed ocular events through an individuak dosing schedule based on patients tolerability, therby allowing patients to remain in treatment and continue to derive benefit
Experience or Perceived Burdens and Associated Quality of life impacts of Anemia and Transfusion Dependence in Myelofibrosis: A patient Self-Reported Survey Analysis
The relationship between anemia, transfusion dependence, quality of life and survival in myelofibrosis
Phase I Study of Belantamab Mafodotin in Combination with Standard of Care in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: DREAMM-9 Updated Interim Analysis
(Reused with permission from the American Society of Hematology. © 2024 The Authors. All rights reserved. Officially licensed by ASH for distribution via GSK Medical Affairs Website and reactively by GSK)
Belantamab mafodotin, pomalidomide, and dexamethasone vs pomalidomide, bortezomib, and dexamethasone in patients with relapsed/refractory multiple myeloma: Patient-reported outcomes from DREAMM-8
Bortezomab, daratumumab and lenalidomide were the most used drugs in the first line of treatment of multiple myeloma in Brazil
Real-World Evidence of Proteasome Inhibitors, Immunomodulatory Drugs and Anti-CD38 in Patients with Multiple Myeloma Treated in Brazil: TOTEMM-B Study Preliminary Insights
Bortezomab, daratumumab and lenalidomide were the most used drugs in the first line of treatment of multiple myeloma in Brazil
First-Line Treatment Landscape in Multiple Myeloma: Preliminary Analysis of Stem Cell Transplantation and Drug Utilization in Brazil and Argentina from the TOTEMM-A and TOTEMM-B
Bortezomab, daratumumab and lenalidomide were the most used drugs in the first line of treatment of multiple myeloma in Brazil
The Impact of Patient-Reported Adverse Events on Quality of life: An Analysis of the DREAMM-7 and DREAMM-8 Randomized Controlled Trials
(Reused with permission from the American Society of Hematology. © 2024 The Authors. All rights reserved. Officially licensed by ASH for distribution via GSK Medical Affairs Website and reactively by GSK)
Final overall survival (OS) in patients with newly diagnosed advanced ovarian cancer (OC) treated with niraparib first-line (1L) maintenance: results from PRIMA/ENGOT-OV26/GOG-3012
Presented at ESMO 2024 by Antonio Gonzalez-Martin
Safety of neoadjuvant PARP inhibitor and immunotherapy in locally advanced HPV-negative head and neck squamous cell carcinoma (PRIME H&N Study)
Presented at ESMO 2024 by Luigi Lorini
Belantamab Mafodotin Plus Pomalidomide and Dexamethasone vs Pomalidomide Plus Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: A Subset Analysis on Patients Who Have Received 1 Prior Line of Therapy Including Lenalidomide (Reused with permission from the American Society of Hematology. © 2024 The Authors. All rights reserved. Officially licensed by ASH for distribution via GSK Medical Affairs Website and reactively by GSK)
(Reused with permission from the American Society of Hematology. © 2024 The Authors. All rights reserved. Officially licensed by ASH for distribution via GSK Medical Affairs Website and reactively by GSK)
Efficacy Outcomes by Minimal Residual Disease (MRD) Negativity Status in Patients With Relapsed or Refractory Multiple Myeloma Treated with Belantamab Mafodotin Plus Bortezomib and Dexamethasone vs Daratumumab, Bortezomib and Dexamethasone: Analysis from the DREAMM-7 trial
(Reused with permission from the American Society of Hematology. © 2024 The Authors. All rights reserved. Officially licensed by ASH for distribution via GSK Medical Affairs Website and reactively by GSK)
Belantamab Mafodotin, Bortezomib, and Dexamethasone vs Daratumumab, Bortezomib, and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Overall Survival Analysis and Updated Efficacy Outcomes of the DREAMM-7 Phase 3 Trial
(Reused with permission from the American Society of Hematology. © 2024 The Authors. All rights reserved. Officially licensed by ASH for distribution via GSK Medical Affairs Website and reactively by GSK)
Population Pharmacokinetics and Exposure-Response Analyses for Belantamab Mafodotin in Combination with Standard of Care in Transplant-Ineligible Newly Diagnosed Multiple Myeloma from DREAMM-9
(Reused with permission from the American Society of Hematology. © 2024 The Authors. All rights reserved. Officially licensed by ASH for distribution via GSK Medical Affairs Website and reactively by GSK)
Outstanding benefit in patients on niraparib maintenance in recurrent platinum-sensitive high-grade ovarian cancer (PSROC): a subanalysis of the GEICO-88R study
Presented at ESMO 2024 by Juan F. Cueva
Stereotactic radiotherapy alone or followed by niraparib for oligometastases or oligoprogression in ovarian cancer following PARP inhibitor therapy – SOPRANO Trial
Presented at ESMO 2024 by Susana Banerjee
Pharmacological Comparison of Dostarlimab and Pembrolizumab in Metastatic Non-Small Cell Lung Cancer in PERLA
Presented at ESMO 2024 by David Spigel
Impact of investigator-assessed response to dostarlimab on quality of life in the RUBY trial of primary advanced or recurrent endometrial cancer
Presented at IGCS 2024 by Noelle Cloven
Efficacy and safety of dostarlimab plus chemotherapy in patients with endometrial cancer by age category in part 1 of the RUBY trial.
Presented at IGCS 2024 by Michael A. Gold
Myelofibrosis Management Recommendations with a Focus on Patients with Cytopenias
The incidence, prevalence, and risk factors of epithelial ovarian cancer along with the current landscape for treatment and the evolving role of PARP inhibitors.
The Risk of Infections in Multiple Myeloma in the Era of Novel Agents
The incidence, prevalence, and risk factors of epithelial ovarian cancer along with the current landscape for treatment and the evolving role of PARP inhibitors.
Myelofibrosis patients: the impact of anemia on quality of life
Impact of anemia and burden of disease on patients with anemia and myelofibrosis and their caregivers.
Belantamab Mafodotin*
Anti-BCMA immunoconjugate Belantamab mafodotin binds to B-cell maturation antigen and eliminates myeloma cells by a multimodal mechanism. *In-license or other partnership with third party
Overview of Myelofibrosis
The incidence, prevalence, and risk factors of epithelial ovarian cancer along with the current landscape for treatment and the evolving role of PARP inhibitors.
Overview of Ovarian Cancer
The incidence, prevalence, and risk factors of epithelial ovarian cancer along with the current landscape for treatment and the evolving role of PARP inhibitors.
Momelotinib mechanism of action
Momelotinib inhibits key drivers of myelofibrosis: dysregulated signalling in the JAK-STAT pathway and hyperactivation of the ACVR1 pathway.
GALAXIES Lung-201: Phase 2, Randomized, Open-label, Platform Study of Belrestotug Plus Dostarlimab in Patients (pts) With First-Line (1L) Locally Advanced/Metastatic (LA/M) Programmed Death Ligand 1 (PD-L1) High (TPS >/=50%) Non-Small Cell Lung Cancer (NSCLC)
Presented at ESMO 2024 by David Spigel
JADE: A phase 3 study to evaluate dostarlimab vs placebo as sequential therapy after chemoradiation in patients with locally advanced unresected head and neck squamous cell carcinoma
Presented at ESMO 2024 by Jean-Pascal Machiels
Re-VOLVE: a phase II clinical trial in women with ovarian cancer progressing post-PARP inhibitor with treatment adapted to real-time assessment of evolving genomic resistance
Presented at ESMO 2024 by Pamela Soberanis
Mismatch Repair Deficient, Stage II/III Rectal Cancer: Real-World Patient, Tumour, and Treatment Characteristics in the Netherlands
Presented at ESMO 2024 by Renee A. Lunenberg
Results of phase 1 clinical trial of belantamab mafodotin combined with carfilzomib, lenalidomide, and dexamethasone for multiple myeloma after one prior line of therapy
Bortezomab, daratumumab and lenalidomide were the most used drugs in the first line of treatment of multiple myeloma in Brazil
Post-progression survival outcomes in patients (pts) with primary advanced or recurrent endometrial cancer (pA/rEC) in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial who received follow-up immunotherapy
Presented at ESMO 2024 by Masoor Raza Mirza
Impact of investigator-assessed response on overall survival (OS) in patients (pts) with primary advanced or recurrent endometrial cancer (pA/rEC) in the ENGOT-EN6-NSGO/GOG3031/RUBY trial
Presented at ESMO 2024 by Cara Mathew
Niraparib
PARP inhibitor Poly ADP ribose polymerases (PARPs) family of enzymes which are involved in many functions, including DNA repair, gene expression, cellular signaling, and base excision repairs. PARP inhibition induces cell death through synthetic lethality.
Dostarlimab
Anti-PD-1 antibody Programmed cell death protein 1 (PD-1), an immune checkpoint molecule that interacts with the PD-1 ligands PD-L1 and PD-L2 to limit T-cell-mediated immune response.
Cobolimab
Anti-TIM-3 Antibody Cobolimab a selective humanized anti-TIM-3 IgG4 monoclonal antibody that enhances T-cell activation.
Load more
Thank you for your query. We're sorry, but we don't find information about this topic:
Here are some steps that you can take to improve the accuracy of your search:
- Check the spelling of your search.
- Try a different wording.
- Reset or review the filters applied (if filters were used to perform this search).
- Check the accuracy of your search terms.
- Try using multiple keywords to narrow down your search.
- Try using synonyms or related words to broaden your search.
